Quick Answer
TG THERAPEUTICS, INC. reported Operating Income Loss of $123.32 million for the year ending 2025.
- TG THERAPEUTICS, INC. showed an increase of +194.1% in Operating Income Loss from 2024 to 2025.
- This data is from TG THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: -$515.6 thousand | Q3 2011: -$30.1 thousand | Q1 2012: -$17.39 million | Q2 2012: -$3.10 million | Q3 2012: -$2.71 million | Q1 2013: -$3.71 million | Q2 2013: -$6.63 million | Q3 2013: -$4.65 million | Q1 2014: -$7.61 million | Q2 2014: -$11.96 million | Q3 2014: -$17.44 million | Q1 2015: -$14.60 million | Q2 2015: -$17.11 million | Q3 2015: -$13.83 million | Q1 2016: -$13.99 million | Q2 2016: -$16.02 million | Q3 2016: -$24.93 million | Q1 2017: -$27.67 million | Q2 2017: -$28.43 million | Q3 2017: -$31.59 million | Q1 2018: -$41.58 million | Q2 2018: $44.35 million | Q3 2018: -$34.33 million | Q1 2019: -$34.69 million | Q2 2019: -$35.54 million | Q3 2019: -$60.86 million | Q1 2020: -$50.25 million | Q2 2020: -$50.85 million | Q3 2020: -$85.72 million | Q1 2021: -$89.20 million | Q2 2021: -$77.49 million | Q3 2021: -$85.13 million | Q1 2022: -$66.87 million | Q2 2022: -$38.94 million | Q3 2022: -$34.96 million | Q1 2023: -$36.99 million | Q2 2023: -$44.67 million | Q3 2023: $114.78 million | Q1 2024: -$9.27 million | Q2 2024: $8.82 million | Q3 2024: $12.43 million | Q1 2025: $8.62 million | Q2 2025: $34.84 million | Q3 2025: $29.37 million.
- Over the full 15 years of available data (2011 to 2025), TG THERAPEUTICS, INC.'s Operating Income Loss has grown by 14,082.7%.
- Historical annual values: Fiscal year 2025: $123.32 million | Fiscal year 2024: $41.93 million | Fiscal year 2023: $20.63 million | Fiscal year 2022: -$218.32 million | Fiscal year 2021: -$344.77 million | Fiscal year 2020: -$273.59 million | Fiscal year 2019: -$169.06 million | Fiscal year 2018: -$174.40 million | Fiscal year 2017: -$118.71 million | Fiscal year 2016: -$78.97 million | Fiscal year 2015: -$63.18 million | Fiscal year 2014: -$55.72 million | Fiscal year 2013: -$22.97 million | Fiscal year 2012: -$26.90 million | Fiscal year 2011: -$882.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: